Previous studies have shown that intravenous injection of OXT, which specifically binds to pathologically upregulated OXTR, can reduce the levels of inflammatory cytokines and alleviate AD pathological damage by blocking the ERK/p38 MAPK and COX‐2/iNOS NF‐κB signaling pathways [46]. The gene discussed is OXTR; the disease is Alzheimer disease.